Objective: To present an up-to-date and practical review of how to safely withdraw glucocorticosteroid therapy.
Introduction
Since their introduction to clinical practice, 60 years ago, corticosteroids have been widely used for the treatment of a great variety of diseases and they are the most powerful of all known anti-inflammatory agents. 1, 2 Their use has considerably reduced morbidity and mortality among people with serious conditions, such as autoimmune diseases, allergic processes, organ transplantation, adrenal insufficiency, congenital adrenal hyperplasia, and others. [3] [4] [5] Nevertheless, when treatment is prolonged and/or corticosteroid doses are high, in addition to the significant side-effects associated with treatment (Cushing's syndrome), suspension or withdrawal in an inappropriate manner can cause three complications:
secondary adrenal insufficiency due to suppression of the hypothalamus-pituitary-adrenal axis (HPA), steroid withdrawal or deprivation syndrome and reactivation of the underlying disease. 1, 6 In view of the large number of pediatric patients who are prescribed treatment with corticosteroids, the objective of this article is to provide an up-to-date and practical review of how to safely suspend corticosteroid therapy when patients have been on it for long periods or at high doses. In order to accomplish this the physiology and pharmacology of corticosteroids will be briefly reviewed, describing the principal syndromes associated with their withdrawal. The literature review was based on searches of the MEDLINE and LILACS databases, selecting the most current and most representative articles on the subject published between 1997 and 2007, and also text books on the subject.
The physiology of corticosteroids
The adrenal gland is made up of two functional units: the medulla and the cortex. The hormones adrenaline and noradenaline are produced in the medulla. The adrenal cortex accounts for 90% of the gland, surrounding the centrally-located medulla. Histologically, the adrenal cortex is subdivided into the zona glomerulosa, the zona fasciculata and the zona reticularis, which produce three classes of hormones: mineralocorticoids, glucocorticoids and androgens. 7 The zona fasciculata is responsible for the synthesis of glucocorticoids, of which group cortisol (hydrocortisone) is the primary representative. Cortisol secretion is controlled by corticotrophin or adrenocorticotrophic hormone (ACTH), which is secreted by the anterior pituitary, which in turn is regulated by a hypothalamic hormone, corticotrophin-releasing hormone (CRH). 8 Both ACTH and CRH are controlled by cortisol through a feedback mechanism, i.e., the greater the plasma cortisol concentration, the less ACTH and CRH are released, and the lower the serum cortisol levels, the greater the amount of ACTH and CRH that is released. The HPA axis exhibits a circadian or nyctohemeral rhythm. In individuals with a normal sleep/wake rhythm, the highest concentrations of ACTH and cortisol occur during the early morning, at 6 and 8 am respectively, decreasing during the afternoon (50% of the morning level by 4 pm) and reaching their lowest levels at around midnight. 9 In addition to these endocrinal stimuli, cortisol secretion is also regulated by neural stimuli originating in the central nervous system and triggered by stressful situations, which explains the elevated serum cortisol levels observed in these situations. 8 Once in circulation, 75-80% of the cortisol binds with a transport protein, an alpha-globulin called transcortin or cortisol binding globulin (CBG). Only a small fraction (6%) exists as a free hormone, and passes through cell membranes binding to specific plasma receptors. 10 The hormone-receptor complex enters the nucleus where it will stimulate, suppress or influence the process of protein synthesis by means of interaction with DNA (genomic action) or with proteins involved in the transcription process (non-genomic action). 8, 11 A third mechanism which was not dependent on intra-nuclear action could explain the rapid action of some corticosteroids, which supports their use for pulse therapy. 9 Cortisol is metabolized by the hepatic cells and its products, more polar and water-soluble, are excreted by the liver and kidneys. 7 
Secondary adrenal insufficiency (suppression of the

HPA axis)
The most feared complication of abrupt withdrawal of prolonged or high-dose corticosteroid therapy is suppression of the HPA axis, which leads to secondary adrenal insufficiency. 16, 21 Suppression may be partial or total, as a result of atrophy of the adrenal glands. 6 Since there is a great deal of individual variability in susceptibility to suppression of the HPA axis after use of exogenous corticosteroids, it is not possible to predict with confidence which patients will be affected even when factors such as dose and duration of corticosteroid therapy are taken into account. [22] [23] [24] Therefore, its true prevalence remains unknown. Some studies have considered it to be fairly infrequent due to the fact that physicians are taught to gradually reduce corticosteroid doses, thereby allowing the HPA axis activity to recover. [22] [23] [24] [25] However, recent reports have indicated that incorrect withdrawal of corticosteroids from patients who have been on them for prolonged periods is the primary cause of adrenal crises and secondary adrenal insufficiency. 26, 27 The symptomology of chronic adrenal insufficiency is char- hours.
Steroid withdrawal or deprivation syndrome
When a patient is unable to tolerate withdrawal of a glucocorticoid, in the absence of an acute relapse of the underlying disease subjacent and in the absence of HPA axis suppression, they are defined as having steroid withdrawal syndrome. 18, 19, 30 Clinical status is characterized by physical or psychological dependence. 31 Physical dependence is characterized by anorexia, nausea, vomiting, weight loss, asthenia, headache, myalgia, arthralgia, postural hypotension, tachycardia, fever and flaky skin. 5, 18, 30, 32 Psychological dependence can manifest as variable degrees of adverse psychological effects. Mood swings and emotional lability are the most common manifestations, followed by delirium and psychotic states. Children and adolescents are also vulnerable to the effects of the steroid withdrawal syndrome, which can occur even when the medication is still being given at supraphysiological levels. 6, 33, 34 The mechanisms responsible for steroid withdrawal syndrome are not yet certain. Nevertheless, it is thought that several mediators may be involved, including CRH, vasopressin, proopiomelanocortin, cytokines (interleukin 1 and 6, tumor necrosis factor alpha) prostaglandins (phospholipase A2) and also changes to the noradrenergic and dopaminergic systems.
19,30 Diagnosis is established by demonstrating HPA axis integrity in the presence of symptoms that would suggest adrenal insufficiency. 6 The syndrome is self-limiting, with a duration that varies from 6 to 10 months, and can be easily treated with a temporary increase in corticosteroid dose, followed by slow withdrawal.
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Relapse of the underlying disease
Recrudescence of the underlying disease is diagnosed is not specific, it must be documented through laboratory test results. 6,37 Graber et al., 38 in 1965, studied recovery of the HPA axis in chronic corticosteroid users, demonstrating that the first parameter to normalize was baseline ACTH (after 2-5 months), followed by baseline serum cortisol (after 6-9 months) and finally cortisol after stimulation with ACTH (after 9 months) ( Table 2 ).
Tests not involving stimulation, such as measurement of reference values that will be useful to studies that investigate adrenal insufficiency in the future. 42 Determination of free cortisol in 24-hour urine is not indicated for assessing lack of HPA axis function since less than 1% of free cortisol is excreted in urine. 28 Therefore, this test is more used to assess hypercortisolism, which is a situation in which transcortin saturation occurs, thereby making increased excretion of free cortisol in urine possible.
For these reasons, inhibition and recovery of the HPA axis is best assessed by means of challenge tests (insulin, metyrapone, CRH, ACTH) or, in some cases, during situations involving clinical stress, such as surgery, trauma or severe despite ongoing discussions related to the fact that it only assesses adrenal function, rather than providing information on the integrity of the HPA axis. 39 Although the low, "more physiological" dose has been described as being more sensitive than the high dose (standard), 14, 44 it is little used due to the need for dilution and because it is unfamiliar to physicians. 37 The stimulus test with high doses of ACTH is carried out as follows: after withdrawal of corticosteroid therapy for at least 24 hours, morning baseline serum cortisol is assayed at 7-8 am (reference value: 5-25 mcg/dL), 250 mcg of synthetic ACTH is administered intravenously and, after 30 and 60 minutes, serum cortisol is assayed again. 6, 11, 44 The normal response is that after the stimulus cortisol rises to 20 mcg/dL or increases more than 10 mcg/dL with relation to base- Due to these limitations, when planning withdrawal of corticosteroid therapy, it is prudent to start from the assumption that the HPA axis will be suppressed. Four basic questions should be answered before initiating corticosteroid withdrawal, as will be shown below.
What is the underlying disease for which the corticosteroids are being used?
The majority of patients who exhibit difficulties with withdrawal of corticosteroid therapy are suffering from severe hematological, inflammatory or immunological diseases.
Therefore, the treating physician must be aware of which signs and symptoms indicate recrudescence of the subjacent disease, which in turn will provide information on speed of corticosteroid withdrawal, or even whether temporary dosage increases will be necessary. If, on the other hand, there is no underlying disease to be treated, such as, for example, in situations where a corticosteroid was used to treat an allergic reaction which has already been resolved, the anti-inflammatory dosage can be abruptly reduced to a physiological dose without risk of adrenal insufficiency. What are the reasons for starting and discontinuing corticosteroid therapy?
The reasons for initiating treatment with corticosteroids vary greatly, due to the multiple therapeutic uses of this class of drugs. Withdrawal is considered when their use is no longer recommended or when significant side-effects appear. Exacerbation of herpetic keratitis is one of the rare contraindications to continuation of corticosteroid therapy. 1 should always be taken in a single dose during the morning.
Short acting preparations, such as hydrocortisone and cortisone acetate, can be taken in two doses, on waking and late afternoon, splitting the total dose into 2/3 in the morning and 1/3 in the afternoon. 6 Although corticosteroids administered via systemic routes, particularly parenterally, are responsible for more complications, this is not the only regime to cause adrenal insufficiency. 40 Other routes of administration (transdermal, intranasal, inhalation, intra-ocular and intra-articular) can also cause of systemic effects, depending on the quantity of the drug that reaches the circulation. 14 Dermatological corticosteroid therapy for prolonged periods, or when used over a large proportion of the body surface area, can cause HPA axis suppression. 3 The same can occur when intranasal corticosteroids are used for prolonged periods or in high doses. 45 
Does the patient have cushingoid features?
Patients with cushingoid symptomology due to corticosteroid therapy will probably have a suppressed HPA axis and adrenal atrophy, requiring greater care with withdrawal of the corticosteroid.
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Corticosteroid therapy withdrawal regimes
There are several regimes for withdrawing corticosteroid therapy, although there are no consensus documents, directives or controlled clinical trials to provide guidance on how to proceed with withdrawal. In clinical practice, the majority of the physicians who prescribe corticosteroids develop their own withdrawal regimes on an empirical basis. 6, 22 What all of them have in common is that withdrawal should never be abrupt.
In general, patients given acute corticosteroid therapy (< 7-14 days) do not develop HPA axis suppression. Therefore, treatment can be suspended with no need for any type of reduction regime. 1, 12, 48, 49 Where therapy has been chronic, the objective is to rapidly reduce the therapeutic dose to a physiological level and then proceed with slower withdrawal thereafter in order to permit the HPA axis to recover. In this situation patients can be divided into two groups: with and without underlying diseases. The category of chronic therapy with underlying disease includes individuals with severe diseases who have been using high doses of corticosteroids for prolonged periods.
Before initiating withdrawal of corticosteroid therapy, it is recommended that all available clinical, biochemical and laboratory data on the activities status of the subjacent disease be collected in order that signs of resurgence can be promptly identified and, if necessary, the doses prescribed can be increased. Patients who have been using corticosteroids for "prolonged" periods and whose underlying disease has been resolved can have their therapeutic dosage reduced to a physiological dose more quickly since there is no risk of further acute occurrences of the symptoms that prompted the drug to be prescribed. Irrespective of group (chronic therapy with or without underlying disease), if corticosteroid withdrawal or adrenal insufficiency symptomology appear, the dose being used at the time should be elevated or maintained for longer.
Kountz & Clark 3 recommend reducing corticosteroids gradually until a dose of 5 mg/day of prednisone or equivalent is reached. The patient will then remain on this dosage for 4 weeks, after which period the ACTH test will be used. If
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the response is abnormal, the dose should be modified to 5 mg on alternate days and the ACTH test repeated until normalization occurs. With this regime, any stressful situations should be treated by increasing the corticosteroid dose to 25-300 mg/day of hydrocortisone or equivalent.
3 Table 3 illustrates the reduction regime used at our center. It is important to be aware that not every patient will need an increased dose in stressful situations. For example, a patient on 50 mg/m 2 /day of hydrocortisone or equivalent, will not need an increased dose in cases of mild or minimal stress, since the dose being used already "covers" such stress situations. On the other hand, a patient on physiological doses of hydrocortisone will need to increase their dose by three times for mild stresses, five times for moderate stresses and up to 10 to 15 times for severe stress.
Corticosteroid supplementation in stressful situations
Stress occurs as a result of the body's attempts to maintain homeostasis in the face of an adverse event, and the HPA axis and the sympathetic nervous system are the primary Corticosteroid therapy can be withdrawn in a single step with no need for a reduction regime.
Chronic treatment with no underlying disease Substitute corticosteroids with prolonged action → intermediate action → short action.
Modify multiple doses per a posology to single morning doses.
Change from daily use to alternate days. Alternatively, when the laboratory tests above cannot be carried out, patients who have used corticosteroids for prolonged periods can be considered as having suppression of the HPA axis up to 1 year after suspension of corticosteroid therapy.
Chronic treatment with underlying disease
The regime is similar to that for chronic treatment without underlying disease, with the following differences:
The velocity of reduction is dependent on the underlying disease. For example: 10% per week;
If there are signs of resurgence of the underlying disease, return to the previous dose.
Continue reducing within the limitations imposed by the disease, until the ACTH test is normal. ACTH = adrenocorticotrophic hormone; HPA = hypothalamus-pituitary-adrenal axis.
mediators of this response. Practically all forms of stress, whether physical or psychological, cause increased secretion of ACTH, which is followed by a significant increase in blood cortisol levels (3-5 times in mild cases and 10-15 in severe cases). 12, 14 This increased cortisol production is the theoretical basis for supplementing corticosteroids to supraphysiological doses in patients with confirmed or presumed adrenal insufficiency who are subjected to stress. 39 What level of serum cortisol might indicate an appropriate response is
unknown as yet and would probably vary depending on the stress trigger event and HPA axis function. 7 There are countless regimes for supplementing corticosteroids in stress situations. These recommendations are generally empirical and are not based on controlled clinical studies. 14, 40 The only point of consensus between them is that hydrocortisone is the corticosteroid of choice due to its mineralocorticoid action. Since prednisone needs to be converted to prednisolone and cortisone acetate needs to be converted to cortisol, by the action of the 11-beta-hydroxylase type I enzyme in the liver, before they have glucocorticoid action, neither of them are indicated for liver patients.
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Although the ideal regime (dose, frequency and duration)
is subject to debate, the doses recommended currently are lower than have been prescribed in the past, taking into consideration the fact that excessive doses may lead to side effects, such as difficulties with healing, hyperglycemia, immunosuppression and water retention. 39 One of the most often cited studies is a review published in 1994 by Salem et al., which bases its recommendations on different "degrees" of surgical stress, which have been adapted to their clinical equivalent in terms of severity. 50 According to these authors, adolescents and adults should be given 25 mg/day of hydrocortisone when subjected to surgical procedures considered of mild stress (inguinal herniorrhaphy, for example); 50-75 mg/day when subjected to moderate stress surgery (non-laparoscopic cholecystectomy, for example); and 100-150 mg/day when high stress surgery is carried out (heart surgery, for example). The hydrocortisone should be administered every 8 hours for 1-3 days, being withdrawn or returned to the normal dose as soon as the stress is removed. 50 Another regime, also for adults, recommends doubling or tripling the glucocorticoid dose during mild to moderate stress, using 100-150 mg of hydrocortisone via continuous venous infusion in the presence of severe stress or inability to use the oral route. 11 Goichot et al. 23 and Salem et al. 
